Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy

Ezhilarasi Chendamarai, MSc, Poonkuzhali Balasubramanian, Ph.D, Biju George, MD, Kavitha M Lakshmi, MSc, Auro Viswabandhya, Aby Abraham, MD, Rayaz Ahmed, MD, Ansu Abu Alex, MSc, Saravanan Ganesan, MSc, Mammen Chandy, MD, Alok Srivastava, MD, Vikram Mathews, MD

Blood (2011) 118 (21): 941.

https://doi.org/10.1182/blood.V118.21.941.941

Published: 2011

Journal Articles

Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data

Saravanan Ganesan, MSc, Ezhilarasi Chendamarai, MSc, Jayandharan G Rao, PhD, Sangeetha Hareendran, MSc, Ansu Abu Alex, MSc, Rayaz Ahmed, MD, Aby Abraham, MD, Auro Viswabandhya, Biju George, MD, Alok Srivastava, MD, Vikram Mathews, MD

Blood (2011) 118 (21): 947.

https://doi.org/10.1182/blood.V118.21.947.947

Published: 2011

Journal Articles

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Vikram Mathews, MD, Biju George, MD, Farah Jijina, MD, Cecil Ross, MD, Reena Nair, MD, Shashikant Apte, MD, Geetha Narayanan, MD, Atul Sharma, MD, Kavitha M Lakshmi, MSc, Auro Viswabandya, MD, Ezhilarasi Chendamarai, MSc, Poonkuzhali Balasubramanian, Ph.D, Vivi Srivastava, MD, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2011) 118 (21): 426.

https://doi.org/10.1182/blood.V118.21.426.426

Published: 2011

Journal Articles

Minimal Residual Disease Monitoring in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with Arsenic Trioxide

Ezhilarasi Chendamarai, MSc, Poonkuzhali Balasubramanian, PhD, Kavitha Lakshmi, MSc, Auro Viswabandya, MD, Biju George, MD, Alok Srivastava, MD, Mammen Chandy, MD, Vikram Mathews, MD

Blood (2008) 112 (11): 2534.

https://doi.org/10.1182/blood.V112.11.2534.2534

Published: 2008

Journal Articles

Comparison of Clinical Outcomes of Relapsed APL Patients Induced with ATO and Consolidated with Either an Autologous SCT or ATO Based Treatment Regimen.

Vikram Mathews, MD, Biju George, MD, Ezhilarasi Chendamarai, MSc, Kavitha M. Lakshmi, MSc, Auro Viswabandya, MD, Alok Srivastava, MD, Mammen Chandy, MD

Blood (2007) 110 (11): 2880.

https://doi.org/10.1182/blood.V110.11.2880.2880

Published: 2007

Journal Articles

Kinetics of Molecular Response among Newly Diagnosed Patients with PML-RARα+ Acute Promyelocytic Leukemia Treated with Arsenic Trioxide.

Ezhilarasi Chendamarai, MSc, Kavitha M. Lakshmi, MSc, Auro Viswabandya, MD, Alok Srivastava, MD, Mammen Chandy, MD, Vikram Mathews, MD

Blood (2007) 110 (11): 4366.

https://doi.org/10.1182/blood.V110.11.4366.4366

Published: 2007

NARROW

Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy

Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Minimal Residual Disease Monitoring in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with Arsenic Trioxide

Comparison of Clinical Outcomes of Relapsed APL Patients Induced with ATO and Consolidated with Either an Autologous SCT or ATO Based Treatment Regimen.

Kinetics of Molecular Response among Newly Diagnosed Patients with PML-RARα+ Acute Promyelocytic Leukemia Treated with Arsenic Trioxide.

Email alerts

ASH Publications

American Society of Hematology

Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy

Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Minimal Residual Disease Monitoring in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with Arsenic Trioxide

Comparison of Clinical Outcomes of Relapsed APL Patients Induced with ATO and Consolidated with Either an Autologous SCT or ATO Based Treatment Regimen.

Kinetics of Molecular Response among Newly Diagnosed Patients with PML-RARα+ Acute Promyelocytic Leukemia Treated with Arsenic Trioxide.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only